These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32673168)

  • 1. Next-Generation Bruton Tyrosine Kinase Inhibitors.
    Stephens DM; Byrd JC
    J Clin Oncol; 2020 Sep; 38(25):2937-2940. PubMed ID: 32673168
    [No Abstract]   [Full Text] [Related]  

  • 2. BTK Inhibitors and Chemoimmunotherapy for CLL.
    Thompson P
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S22-S24. PubMed ID: 32862855
    [No Abstract]   [Full Text] [Related]  

  • 3. CLL in focus: news in the treatment of chronic lymphocytic leukemia.
    Schuyler D
    Clin Adv Hematol Oncol; 2020 Oct; 18(10):627-628. PubMed ID: 33201868
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA
    Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
    [No Abstract]   [Full Text] [Related]  

  • 6. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
    Lasica M; Tam CS
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):761-773. PubMed ID: 34174985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.
    Shao Y; Kay NE; Gale RP; Liang Y
    Leukemia; 2024 Jul; 38(7):1469-1473. PubMed ID: 38824147
    [No Abstract]   [Full Text] [Related]  

  • 8. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
    Thibaud S; Tremblay D; Bhalla S; Zimmerman B; Sigel K; Gabrilove J
    Br J Haematol; 2020 Jul; 190(2):e73-e76. PubMed ID: 32433778
    [No Abstract]   [Full Text] [Related]  

  • 9. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Tang CPS; McMullen J; Tam C
    Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
    Kim MS; Prasad V
    Cancer; 2020 Oct; 126(19):4270-4272. PubMed ID: 32644193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase.
    Aslan B; Hubner SE; Fox JA; Taverna P; Wierda WG; Kornblau SM; Gandhi V
    Haematologica; 2022 Jan; 107(1):292-297. PubMed ID: 34498444
    [No Abstract]   [Full Text] [Related]  

  • 14. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.
    Huynh T; Rodriguez-Rodriguez S; Danilov AV
    Mol Cancer Ther; 2024 May; 23(5):619-626. PubMed ID: 38693903
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
    Wimalachandra M; Basu TN; Salisbury J; Attard N; Calonje E; Patten PEM
    Clin Exp Dermatol; 2021 Dec; 46(8):1569-1571. PubMed ID: 34028865
    [No Abstract]   [Full Text] [Related]  

  • 16. BTK/PD-1 blockade for treatment of Richter's transformation.
    Tang PS; Tam CS
    Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820
    [No Abstract]   [Full Text] [Related]  

  • 17. Bruton Tyrosine Kinase Inhibitors: Present and Future.
    Burger JA
    Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.
    Bossory Goike L; Dean S
    Vasc Med; 2020 Jun; 25(3):281-282. PubMed ID: 32146868
    [No Abstract]   [Full Text] [Related]  

  • 19. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C
    Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Stephens DM; Byrd JC
    Blood; 2021 Sep; 138(13):1099-1109. PubMed ID: 34320163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.